AB-101 in healthy subjects & cHBV patients

A Phase 1a/1b clinical trial evaluating the safety, tolerability, and PK/PD of oral administration of AB-101 in healthy subjects and patients with cHBV infection.

Preliminary data from the single- and multiple-ascending dose portions of this trial shows that AB-101 is well-tolerated and binds to the receptor target.

Clinicaltrials.gov